Munich, Germany — November 18, 2025
Cellbyte, a Munich-based AI-native SaaS platform, has raised $2.75 million in seed funding to help pharmaceutical giants slash drug launch timelines by more than half. The funding round, led by Frontline Ventures with the participation of Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels, positions Cellbyte for rapid international expansion and ambitious hiring plans as the startup triples its headcount and accelerates engineering development.
Founded in 2024 by Daniel Moreira, Felix Steinbrenner, and Samuel Moreira, Cellbyte is built to solve pharma’s most time- and resource-intensive bottleneck: the fragmented, manual preparation of pricing, reimbursement, and regulatory documentation for every new drug launch. Industry insiders estimate that such workflows can delay patient access to life-saving medications by over 12 months, while costing drug companies hundreds of thousands of dollars in external consulting and outdated legacy database fees. With generative AI and agentic data intelligence, Cellbyte enables market access teams to instantly analyze millions of clinical, pricing, HTA, and regulatory data points from across the globe, transforming processes that once took months into minutes.
“Success in pharma depends on launch execution. Insights from vast, interconnected, and current data are essential to optimize pricing, compliance, and speed,” says Co-CEO Felix Steinbrenner. “Industry heavyweights are showing real appetite for faster, smarter, more cost-effective launches—and Cellbyte is delivering exactly that.“
Cellbyte’s traction speaks for itself: Since launch, the startup has scaled to six figures in annual recurring revenue (ARR) within weeks, secured deals with major pharmaceutical firms including Bayer, and expanded coverage in Europe and the US. The new capital will be used to grow its workforce, deepen its engineering capabilities, and meet growing customer demand across global markets as Cellbyte aims to become the “operating system” for commercial pharmaceutical teams.
Daniel Moreira, Co-CEO, adds: “I’ve seen first-hand how critical pricing and market access decisions are still made using outdated, error-prone manual methods. Generative AI is reshaping the landscape—and Cellbyte is leading the charge.”
William McQuillan, Partner at Frontline Ventures, commented on the round: “Felix, Samuel, and Daniel have built a global, AI-powered solution for one of pharma’s biggest process bottlenecks. We’re proud to back their US and Europe expansion, accelerating access to new treatments worldwide.”
Deal Highlights Table
| Metric/Feature | Details & Insights |
|---|---|
| Total Raised | $2.75 million seed, led by Frontline Ventures |
| Growth Trajectory | Six-figure ARR in weeks, rapid enterprise adoption |
| Major Customers | Bayer, other global pharmaceutical leaders |
| Market Problem | 12+ months launch bottlenecks, fragmented data |
| Product Edge | AI-native, real-time insight and automation |
| Expansion Plans | Triples headcount, US and Europe focus |
| Strategic Messaging | “Drug launches in minutes, not months.” |
Cellbyte is set to redefine global drug launches, enabling faster, more intelligent commercial decisions for the world’s leading pharmaceutical companies.
